Antibody-Drug Conjugate Therapeutic Window Enhancement, Upcoming Webinar Hosted by Xtalks
In this free webinar, the featured speakers will discuss Aji Bio-Pharma's novel method of affinity peptide-mediated regiodivergent antibody functionalization that enables the synthesis of antibody-drug conjugates (ADCs) from native IgGs in a tunable and atom-precise manner. Both thiol-based and azide-based site-specific ADCs produced by "AJICAP" technology demonstrate an expansion of their therapeutic index compared with stochastic technology. Takeaways from this webinar include how site-specific conjugation technology coupled with a novel cleavable linker, reduces heterogeneity, thus simplifying manufacturing and characterization of the ADCs, and enhances biological properties by increasing the therapeutic window.
TORONTO, Sept. 15, 2021 /PRNewswire-PRWeb/ -- In this live webinar on Monday, October 4, 2021 at 5pm EDT (2pm PDT), antibody-drug conjugate (ADC) experts Zhala Tawfiq, from Aji Bio-Pharma Services; and Yutaka Matsuda, from Ajinomoto Inc., discuss advantages of next generation ADC technologies, specifically, Ajinomoto's proprietary site-specific conjugation technology called "AJICAP."
Traditional ADCs are synthesized by lysine or cysteine chemistries, and this results in a stochastic distribution of cytotoxic drugs on different sites of the antibody. The heterogeneous nature of these stochastic ADCs can cause diminished efficacy and increased toxicity, thus limiting the corresponding therapeutic index.
To improve on traditional ADC technology, Aji Bio-Pharma developed a novel chemical conjugation platform termed "AJICAP" for the site-specific modification of native antibodies through the use of a class of IgG Fc-affinity reagents. The CMDO is also developing and introducing a novel cleavable linker to increase ADC stability in vivo, demonstrating that this novel cleavable linker is responsive to enzymatic drug release but undergoes almost no premature cleavage.
Overall, Aji Bio-Pharma's site-specific conjugation technology coupled with a novel cleavable linker, reduces heterogeneity, thus simplifying manufacturing and characterization of the ADCs, and enhances biological properties by increasing the therapeutic window. These proprietary ADC technologies bring significant advantages and are a powerful platform to enable next-generation ADCs.
For more information, or to register for this event, visit Antibody-Drug Conjugate Therapeutic Window Enhancement.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Media Contact
Ayesha Rashid, Xtalks, +1 (416) 977-6555 x 272, [email protected]
SOURCE Xtalks
Share this article